ecrin-mdr-crcClinical2006Previously untreated metastatic colorectal cancerPreviously Untreated Metastatic Colorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2518837United Kingdom5XelodaMitomycin-CAvastinECRIN MDRCompletedfalseThe MAX study: A randomised phase II/III study to evaluate the role of Mitomycin C, Avastin and Xeloda in patients with untreated metastatic colorectal cancerPrimary objectives: Phase II stagePrimary Objective:• To determine the relative toxicity of the combination of capecitabine andbevacizumab and the combination of capecitabine, mitomycin C (MMC) andbevacizumab with that of capecitabine monotherapy. Phase III stagePrimary Objective:• To compare progression-free survival (PFS) on the three arms Primary endpoints: Phase II stagePrimary Endpoint: Treatment-related toxicity Phase III stagePrimary endpoint: Progression free survival (PFS)2006-05-1525188372005-005761-11